TrialJournal of gynecologic oncology2025

Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.

Yong-Man Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.